These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 7648281)

  • 1. A vaccinia-gp160-based vaccine but not a gp160 protein vaccine elicits anti-gp160 cytotoxic T lymphocytes in some HIV-1 seronegative vaccinees.
    Perales MA; Schwartz DH; Fabry JA; Lieberman J
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Sep; 10(1):27-35. PubMed ID: 7648281
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An HIV-1 envelope protein vaccine elicits a functionally complex human CD4+ T cell response that includes cytolytic T lymphocytes.
    Stanhope PE; Liu AY; Pavlat W; Pitha PM; Clements ML; Siliciano RF
    J Immunol; 1993 May; 150(10):4672-86. PubMed ID: 8097759
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HIV-1 soluble antigens induced CD8+ cytotoxic T-cell responses in an immunized individual.
    Achour A; Moukrim Z; Picard O; Bizzini B; Burny A; Zagury D
    Cell Mol Biol (Noisy-le-grand); 1995 May; 41(3):395-400. PubMed ID: 7580833
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of cytotoxic T cell responses to candidate HIV-1 vaccines in HIV-1-uninfected individuals.
    McElrath MJ; Corey L; Greenberg PD
    AIDS Res Hum Retroviruses; 1994; 10 Suppl 2():S69-72. PubMed ID: 7865336
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Studies of the mechanism of cytolysis by HIV-1-specific CD4+ human CTL clones induced by candidate AIDS vaccines.
    Miskovsky EP; Liu AY; Pavlat W; Viveen R; Stanhope PE; Finzi D; Fox WM; Hruban RH; Podack ER; Siliciano RF
    J Immunol; 1994 Sep; 153(6):2787-99. PubMed ID: 7915742
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improving recombinant MVA immune responses: potentiation of the immune responses to HIV-1 with MVA and DNA vectors expressing Env and the cytokines IL-12 and IFN-gamma.
    Abaitua F; Rodríguez JR; Garzón A; Rodríguez D; Esteban M
    Virus Res; 2006 Mar; 116(1-2):11-20. PubMed ID: 16214252
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Resistance to human immunodeficiency virus 1 infection of SCID mice reconstituted with peripheral blood leukocytes from donors vaccinated with vaccinia gp160 and recombinant gp160.
    Mosier DE; Gulizia RJ; MacIsaac PD; Corey L; Greenberg PD
    Proc Natl Acad Sci U S A; 1993 Mar; 90(6):2443-7. PubMed ID: 8460155
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunization with subunit human immunodeficiency virus vaccine generates stronger T helper cell immunity than natural infection.
    Clerici M; Tacket CO; Via CS; Lucey DR; Muluk SC; Zajac RA; Boswell RN; Berzofsky JA; Shearer GM
    Eur J Immunol; 1991 Jun; 21(6):1345-9. PubMed ID: 1845391
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytotoxic T lymphocytes from HIV-1 seropositive individuals recognize immunodominant epitopes in Gp160 and reverse transcriptase.
    Lieberman J; Fabry JA; Kuo MC; Earl P; Moss B; Skolnik PR
    J Immunol; 1992 May; 148(9):2738-47. PubMed ID: 1374097
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Determinants of antibody response after recombinant gp160 boosting in vaccinia-naive volunteers primed with gp160-recombinant vaccinia virus. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Clinical Trials Network.
    Graham BS; Gorse GJ; Schwartz DH; Keefer MC; McElrath MJ; Matthews TJ; Wright PF; Belshe RB; Clements ML; Dolin R
    J Infect Dis; 1994 Oct; 170(4):782-6. PubMed ID: 7930718
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IL-12 delivery from recombinant vaccinia virus attenuates the vector and enhances the cellular immune response against HIV-1 Env in a dose-dependent manner.
    Gherardi MM; Ramirez JC; Rodríguez D; Rodríguez JR; Sano G; Zavala F; Esteban M
    J Immunol; 1999 Jun; 162(11):6724-33. PubMed ID: 10352291
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cellular and humoral immune responses to a canarypox vaccine containing human immunodeficiency virus type 1 Env, Gag, and Pro in combination with rgp120.
    AIDS Vaccine Evaluation Group 022 Protocol Team
    J Infect Dis; 2001 Feb; 183(4):563-70. PubMed ID: 11170981
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cross-clade envelope glycoprotein 160-specific CD8+ cytotoxic T lymphocyte responses in early HIV type 1 clade B infection.
    Wilson SE; Pedersen SL; Kunich JC; Wilkins VL; Mann DL; Mazzara GP; Tartaglia J; Celum CL; Sheppard HW
    AIDS Res Hum Retroviruses; 1998 Jul; 14(11):925-37. PubMed ID: 9686639
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficient CD8+ T cell response to the HIV-env V3 loop epitope from multiple virus isolates by a DNA prime/vaccinia virus boost (rWR and rMVA strains) immunization regime and enhancement by the cytokine IFN-gamma.
    Gómez CE; Abaitua F; Rodríguez D; Esteban M
    Virus Res; 2004 Sep; 105(1):11-22. PubMed ID: 15325077
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytotoxic T cell repertoire selection. A single amino acid determines alternative class I restriction.
    Bergmann CC; Tong L; Cua RV; Sensintaffar JL; Stohlman SA
    J Immunol; 1994 Jun; 152(12):5603-12. PubMed ID: 7515908
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Production of transmembrane and secreted forms of tumor necrosis factor (TNF)-alpha by HIV-1-specific CD4+ cytolytic T lymphocyte clones. Evidence for a TNF-alpha-independent cytolytic mechanism.
    Liu AY; Miskovsky EP; Stanhope PE; Siliciano RF
    J Immunol; 1992 Jun; 148(12):3789-98. PubMed ID: 1351088
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhancement of human immunodeficiency virus (HIV)-specific CD4+ and CD8+ cytotoxic T-lymphocyte activities in HIV-infected asymptomatic patients given recombinant gp160 vaccine.
    Kundu SK; Katzenstein D; Moses LE; Merigan TC
    Proc Natl Acad Sci U S A; 1992 Dec; 89(23):11204-8. PubMed ID: 1360665
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Production of long-lived neutralizing antibodies to HIV-1 IIIB in mice with a vaccinia recombinant virus-infected cell vaccine expressing gp160.
    Parry C; McLain L; Dimmock NJ
    AIDS Res Hum Retroviruses; 1994 Feb; 10(2):205-12. PubMed ID: 8198873
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vaccination of vaccinia-naive adults with human immunodeficiency virus type 1 gp160 recombinant vaccinia virus in a blinded, controlled, randomized clinical trial. The AIDS Vaccine Clinical Trials Network.
    Graham BS; Belshe RB; Clements ML; Dolin R; Corey L; Wright PF; Gorse GJ; Midthun K; Keefer MC; Roberts NJ
    J Infect Dis; 1992 Aug; 166(2):244-52. PubMed ID: 1353102
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase I evaluation of the safety and immunogenicity of vaccination with recombinant gp160 in patients with early human immunodeficiency virus infection. Military Medical Consortium for Applied Retroviral Research.
    Redfield RR; Birx DL; Ketter N; Tramont E; Polonis V; Davis C; Brundage JF; Smith G; Johnson S; Fowler A
    N Engl J Med; 1991 Jun; 324(24):1677-84. PubMed ID: 1674589
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.